Regenerative Medical Solutions (LAB RMS) is a Swiss held regenerative medicine company specialising in peptide research and product formulations to lead a evolution in medical breakthrough technologies.
Founded as a research division in 2010 through a joint-venture between Switzerland-based Lab Dom (Suisse) Inc. and Australian-based RMS International, the company has funded extensive investment in research and development to create market-leading biopharmaceutical solutions based on modern peptide therapy for aesthetic, sports and regenerative medicine application.
With cornerstone technologies, state-of-the-art research facilities, as well as a brilliant lineup of global experts in cellular biology, stem cell and biochemistry, LAB RMS is focused on innovations that work and leave a lasting impression of success.
LAB RMS is the rst to pioneer and commercialize a bio-engineered myostatin inhibitor with unique self-regulating mechanism, known as Myopep. It has also introduced a diverse product portfolio including rapid a diverse product portfolio including rapid anti-inammatory agents to combat age-related disease and pain (Regenapep).